Irinotecan Hydrochloride medac 20 mg/ml, concentrate for solution for infusion
Irinotecan Hydrochloride medac is indicated for the treatment of patients with advanced colorectal cancer: ● in combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for advanced disease, ● as a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen. Irinotecan Hydrochloride medac in combination with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFR)-expressing, KRAS wild-type metastatic colorectal cancer, who had not received prior treatment for metastatic disease or after failure of irinotecan-including cytotoxic therapy (see section 5.1). Irinotecan Hydrochloride medac in combination with 5-fluorouracil, folinic acid and bevacizumab is indicated for first-line treatment of patients with metastatic carcinoma of the colon or rectum. Irinotecan Hydrochloride medac in combination with capecitabine with or without bevacizumab is indicated for first-line treatment of patients with metastatic colorectal carcinoma.